ESC 365 - Discussant review - The TITRATE-HF study

HFA Premium Access

Discussant review - The TITRATE-HF study

Session: Late breaking clinical trials: drugs and disease management

Topic: Pharmacotherapy

Speaker: Professor J. Ezekowitz (Edmonton, CA)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Professor Justin Ezekowitz

University of Alberta, Edmonton (Canada)

11 presentations

1 follower

9 more presentations in this session

The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial

Speaker: Professor J. Butler (Dallas, US)

Discussant review - EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mo

Speaker: Professor L. Kober (Copenhagen, DK)

Contemporary guideline-directed medical therapy sequencing and titration in de novo, worsening, and chronic heart failure: first data from the TITRATE-HF study

Speaker: Professor J. Brugts (Rotterdam, NL)

First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure

Speaker: Doctor A. Spahillari (Durham, US)

Discussant review - TEAM-HF: Implementation Study of Accelerated Heart Failure Guideline-Directed Medical Therapy in a General Cardiology Clinic

Speaker: Professor J. Celutkiene (Vilnius, LT)

Access the full session

Late breaking clinical trials: drugs and disease management

Speakers: Professor J. Ezekowitz, Professor J. Butler, Professor L. Kober, Professor J. Brugts, Doctor A. Spahillari...

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources